Close Menu

NEW YORK (360Dx) – InBios announced today that it has received 510(k) clearance from the US Food and Drug Administration for an antibody-based point-of-care, rapid test that detects Chagas disease.

The firm's Chagas Detect Plus Rapid Test Kit, developed in collaboration with the Infectious Disease Research Institute in Seattle, employs an immunochromatographic strip assay to detect human IgG antibodies to Trypanosoma cruzi in human serum and whole blood matrices, including venous and capillary whole blood.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.